A promising new trial that effectively eliminated precancerous HPV types was subject of national and international focus this week. The trial on an experimental immunotherapy Tipapkinogen Sovacivec (TS) was led by Diane Harper, M.D., M.P.H., M.S., professor, and was the focus of an article in The Lancet and a MedPage Oncology/Hematology CME. The TS vaccine effectively eliminated the most severe cervical precancerous lesions without need for surgery. Harper is hopeful. “For women hoping to preserve their cervix, even a 24% clearance of both HPV and abnormal cells is promising, especially since surgery does not clear the causative agent,” she said to the Lancet.